Heroin-related treatment admissions are lower in US states that legalized adult-use cannabis, according to a Pennsylvania State University study published on 19 November 2026. Researchers analysed data from all 50 states between 1992 and 2023.
Key points
- Penn State researchers analysed treatment data from all 50 US states, 1992 to 2023.
- States with adult-use legalization show lower heroin involvement in treatment admissions.
- The study is observational and shows an association, not proof of cause.
The study, reported by NORML, appears in the International Journal of Drug Policy. It compares states with and without adult-use cannabis laws. States with legalization show a lower share of heroin in treatment admissions.
What the researchers analysed
The team used the Treatment Episode Data Set (TEDS), which covers all 50 states. The period runs from 1992 to 2023. Italian outlet ADUC puts the sample at 55 million admissions.
The authors treat cannabis liberalization as a cumulative policy path. It runs from medical-only access up to regulated adult retail sales.
Key figures on heroin admissions
According to ADUC, the results are expressed per 1,000 heroin-related admissions:
- 107 fewer admissions after recreational legalization, compared with continued prohibition.
- 128 fewer admissions once regulated retail sales began.
The strongest evidence concerns the advanced stages of adult-use legalization, compared with states that have no policy. The authors say heroin involvement is lower at those stages, as relayed by NORML.
Earlier research points the same way
Previous observational studies have regularly found an association between cannabis access laws and lower opioid treatment admissions and mortality, according to NORML. This marijuana opioid treatment reduction study adds a long, nationwide dataset to that body of work.
The findings describe a statistical link. The sources do not establish that legalization causes the decline.
Ce que ça change pour toi
For readers in Europe, nothing changes directly. The study covers US states, and it does not alter any European rule or the status of any product.
It could, however, feed policy debates on how cannabis rules relate to opioid harm. Such debates often draw on US data, though results from one country may not carry over to another. If you follow cannabis research, our piece on cannabis and muscle recovery in sports shows how often the evidence stays limited.
For legal CBD products, you can browse the CBD flower collection. Every Spliff product is lab-tested: THC content below 0.3% (0% for vapes and pods). The lab analysis of each batch is available on request from customer service.
FAQ
What did the study find about heroin admissions?
States with adult-use cannabis legalization show lower heroin involvement in treatment admissions than states without it. The effect is strongest in advanced legalization stages.
Does the study prove legalization reduces opioid use?
No. It is observational and reports an association. The sources do not claim a proven cause.
What data did the researchers use?
They used the Treatment Episode Data Set for all 50 US states, covering 1992 to 2023.







